ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 431

Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data

Tsuneyo Mimori1, Masayoshi Harigai2, Tatsuya Atsumi3, Masataka Kuwana4, Syuji Takei5, Naoto Tamura6, Takao Fujii7, Hiroaki Matsuno8, Shigeki Momohara9, Kazuhiko Yamamoto10, Takeshi Kokubo11, Yutaka Endo11, Naonobu Sugiyama11, Tomohiro Hirose11, Yosuke Morishima11 and Noritoshi Yoshii11, 1Kyoto University, Kyoto, Japan, 2Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 3Hokkaido University, Sapporo, Japan, 4Nippon Medical School, Tokyo, Japan, 5Kagoshima University, Kagoshima, Japan, 6Juntendo University, Tokyo, Japan, 7Wakayama Medical University, Wakayama, Japan, 8Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 9Hakkeikai Inc Medical Institution, Shizuoka, Japan, 10University of Tokyo, Tokyo, Japan, 11Pfizer Japan Inc, Tokyo, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Japanese, safety and tofacitinib

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib have been shown in patients (pts) with RA in global Phase (P) 2, P3 (one of which included Japanese pts) and a long-term extension (LTE) study and in two P2 and one LTE study in Japanese pts. We evaluated safety of tofacitinib following drug approval in Japanese pts with RA using all-case post-marketing surveillance (PMS) data.

Methods: PMS is a regulatory requirement in Japan; an interim analysis of safety data from an ongoing 3-year PMS study was conducted (4 Mar 2017 data-cut). All Japanese pts with RA receiving tofacitinib were consecutively and prospectively registered in the PMS study and were monitored. Follow-up surveillance after discontinuation of tofacitinib was implemented for 3 years for all adverse events (AEs) from the date of treatment initiation with tofacitinib. A 6-month interim analysis of all AEs and serious AEs (SAEs) was conducted. For AEs of special interest, all-period data was used to calculate cumulative incidence rates (IRs) over time (IRs: pts with events /100 pt-years [pt-yrs]) for herpes zoster (HZ) and serious infection events (SIEs) during treatment +28 days, and for malignancies during the observational period.

Results: Overall, 2882 tofacitinib-treated pts were enrolled and included in the 6-month interim safety analysis: 79.9% were female, mean age 62.6 yrs, with 32.0% pts ≥70 yrs and 1241.4 pt-yrs of exposure. Of these, 686 pts (23.8%) discontinued treatment, mainly due to AEs (276 pts; 9.6%) or lack of effectiveness (260 pts; 9.0%; multiple reasons allowed). At least one AE was observed in 965 pts (33.5%); infections were observed in 367 pts (12.7%); the most frequent AEs were HZ (98 pts; 3.4%) and hepatic function abnormal (48 pts; 1.7%). SAEs occurred in 221 pts (7.7%); the most frequent SAEs were pneumonia (20 pts; 0.7%), HZ (16 pts; 0.6%), interstitial lung disease (14 pts; 0.5%) and condition aggravated (12 pts; 0.4%); serious infections occurred in 101 pts (3.5%). Malignancy (all causality) was reported in 21 pts (0.7%); ovarian cancer, pancreatic carcinoma, lung neoplasm, colon cancer, breast cancer, diffuse large B‑cell lymphoma and lymphoproliferative disorder all occurred in 2 pts (0.07%) each. There were 16 deaths (0.6%) during the 6-month observed period; the most common causes of death (including pts with multiple causes listed) were infection (5 cases, all respiratory infections), malignancy (4 cases) and interstitial lung disease (3 cases). For AEs of special interest from all-period data during treatment +28 days, the IR of HZ (serious and non-serious) was 6.43/100 pt-yrs (160 pts; 2489.5 pt-yrs) and SIEs 5.96/100 pt-yrs (150 pts; 2517.0 pt-yrs), and during the observational period IR malignancy was 1.39/100 pt-yrs (42 pts; 3014.1 pt-yrs).

Conclusion: For this interim analysis, AEs during the initial 6-month treatment period from PMS reports of tofacitinib in Japanese pts did not reveal any new or unexpected safety signals vs the tofacitinib RA clinical program. Final results from this PMS study are awaited in order to make definitive conclusions on the safety profile of tofacitinib in these pts.


 


Disclosure: T. Mimori, Astellas, Ayumi, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi Tanabe, MSD, Sanofi, Taisho Toyama, 2,Astellas, Bristol-Myers Squibb, Chugai, Eisai, Mitsubishi-Tanabe, 8; M. Harigai, Eisai, Takeda, Teijin, 2,Bristol-Myers Squibb, Chugai, Janssen, Pfizer Inc, 5; T. Atsumi, Alexion, Astellas, Bristol-Myers Squibb, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Sanofi, 2,AbbVie, Astellas, Chugai, Eisai, Mitsubishi-Tanabe, Pfizer Inc, Takeda, UCB Japan, 8,Bayer, Daiichi-Sankyo, Takeda, 9; M. Kuwana, Chugai, Eisai, Mitsubishi-Tanabe, Ono, Pfizer Inc, Santen, 2,Astellas, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Ono, Pfizer Inc, UCB, 8; S. Takei, Chugai, Eisai, Mitsubishi-Tanabe, Takeda, 2,Asahi-kasei, Ayumi, Chugai, Mitsubishi-Tanabe, Ono, 8; N. Tamura, AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Takeda, 2,AbbVie, Astellas, Bristol-Myers Squibb, Eisai, Janssen, Mitsubishi-Tanabe, 8; T. Fujii, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, Ono, Pfizer Japan Inc, 2,AbbVie, Mitsubishi-Tanabe, Ono, Pfizer Japan Inc, 8; H. Matsuno, Ayumi, Meiji Seika, Mochida, Nichi-Iko, 5; S. Momohara, AbbVie, Bristol-Myers Squibb, Eisai, Janssen, Mitsubishi-Tanabe, Ono, Pfizer Japan Inc, Takeda, 8; K. Yamamoto, AbbVie, Astellas, Ayumi, Chugai, Eisai, Mitsubishi Tanabe, Nippon Kayaku, Pfizer, Taisho Toyama, Takeda, TEIJIN UCB, 2,Asahikasei, AstraZeneca, Ayumi, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer Inc, Sanofi, Sumitomo Dainippon, Taisho Toyama, Takeda, TEIJIN, Toyama Chemical, UCB, 8; T. Kokubo, Pfizer Japan Inc, 3; Y. Endo, Pfizer Inc, 1,Pfizer Japan Inc, 3; N. Sugiyama, Pfizer Inc, 1,Pfizer Japan Inc, 3; T. Hirose, Pfizer Inc, 1,Pfizer Japan Inc, 3; Y. Morishima, Pfizer Inc, 1,Pfizer Japan Inc, 3; N. Yoshii, Pfizer Inc, 1,Pfizer Japan Inc, 3.

To cite this abstract in AMA style:

Mimori T, Harigai M, Atsumi T, Kuwana M, Takei S, Tamura N, Fujii T, Matsuno H, Momohara S, Yamamoto K, Kokubo T, Endo Y, Sugiyama N, Hirose T, Morishima Y, Yoshii N. Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis: An Interim Report of Safety Data [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/post-marketing-surveillance-of-tofacitinib-in-japanese-patients-with-rheumatoid-arthritis-an-interim-report-of-safety-data/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-marketing-surveillance-of-tofacitinib-in-japanese-patients-with-rheumatoid-arthritis-an-interim-report-of-safety-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology